Form 8-K - Current report:
SEC Accession No. 0001493152-24-034729
Filing Date
2024-09-03
Accepted
2024-09-03 08:56:28
Documents
14
Period of Report
2024-08-30
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 46145
2 ex3-1.htm EX-3.1 9159
  Complete submission text file 0001493152-24-034729.txt   237057

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE mtnb-20240830.xsd EX-101.SCH 3039
4 XBRL LABEL FILE mtnb-20240830_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE mtnb-20240830_pre.xml EX-101.PRE 24181
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3797
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-484-8805
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

EIN.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38022 | Film No.: 241272275
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)